B. Riley Securities upgraded MacroGenics Inc. to a Buy rating on April 10, setting a $9 price target and noting about 13% upside. [1][2]
The upgrade matters because it signals renewed investor confidence in a company operating in a sector recently energized by Gilead Sciences' activity, potentially shifting capital toward smaller biotech firms. A higher rating can attract institutional buyers and lift the stock’s trading range.
B. Riley moved MacroGenics from a Neutral stance to Buy, indicating the firm now expects the company’s fundamentals to outperform the broader market. The analyst team highlighted recent clinical progress and pipeline depth as primary reasons for the shift. This change aligns with the firm’s broader strategy of identifying undervalued biotech opportunities.
The $9 price target reflects B. Riley’s valuation model, which incorporates projected earnings growth and comparable peer multiples. At current trading levels, the target suggests roughly a 13.18% upside potential for investors. The firm expects the stock to benefit from upcoming data releases and potential partnership announcements.
Sector activity has been buoyed by Gilead‑driven developments, with several mid‑cap biotech stocks seeing price appreciation after Gilead announced new collaborations. B. Riley said that this environment creates tailwinds for companies like MacroGenics, which are positioned to capitalize on emerging therapeutic trends.
Analysts anticipate that the upgraded rating could prompt a short‑term rally as traders adjust positions. However, they caution that biotech stocks remain volatile and subject to clinical trial outcomes. Investors are advised to monitor upcoming data releases and regulatory milestones closely.
**What this means:** The Buy rating and $9 target suggest that MacroGenics may outperform many peers if its pipeline advances as expected. The endorsement by B. Riley could draw new capital into the stock, especially from investors seeking exposure to the biotech sector’s growth driven by larger players like Gilead. Market participants should watch for trial data and partnership news that could validate or challenge the projected upside.
“MacroGenics now carries a Buy rating from B. Riley.”
The analyst upgrade signals confidence that MacroGenics can ride broader biotech momentum, potentially delivering returns above the market if its pipeline milestones are met.
